Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted physiotherapy for motor functional neurological disorder
ACTRN12626000250336Phase 2Recruiting
- Sponsor
- University of Melbourne
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of psilocybin in Dissociative neurological symptom disorder (DNSD) (2 arms), sponsored by University of Melbourne. Primary endpoint: Participant-reported changes in functional neurological disorder symptoms. Started Sep 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
Dissociative neurological symptom disorder (DNSD)
Beyond the preview
Go deeper on ACTRN12626000250336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000250336.